• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Imprivata Appoints Gus Malezis as New CEO After Thoma Bravo Acquisition

by HITC Staff 09/20/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 Imprivata Appoints Gus Malezis

Today, healthcare IT security company Imprivata has announced the appointment of Gus Malezis as its new President and Chief Executive Officer, effective September 19, 2016. The appointment comes off the heels of private equity investment firm Thoma Bravo has completed its acquisition of the healthcare IT security company.

Under the terms of the merger agreement, Imprivata shareholders are entitled to receive $19.25 in cash for each share of Imprivata common stock they hold valued at $544M. The deal was announced on July 13 and received approval from Imprivata shareholders on September 14. 

Prior to joining Imprivata, Gus was most recently the President of Tripwire, a leading global provider of endpoint detection and response, security and compliance solutions. Gus has a strong track record of leading growth and innovation for leading technology and security companies such as Tripwire, McAfee, 3Com and Merisel. He combines extensive knowledge of global markets with strong technical knowledge and passion for customer success in the rapidly changing IT marketplace.

“Imprivata is the most impressive company in the healthcare IT security space and their expertise and commitment to customer satisfaction is second to none,” said Gus Malezis, President and Chief Executive Officer of Imprivata. “I’m thrilled to join the company at this important time. We have a phenomenal opportunity to continue to build a great future for Imprivata customers, partners and employees as we deliver on our vision to enable healthcare to access, communicate and transact patient health information in a secure, convenient and transparent process.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Imprivata

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |